StockNews.com Downgrades Can-Fite BioPharma (NYSE:CANF) to Sell

Can-Fite BioPharma (NYSE:CANF) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

CANF has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma in a research note on Thursday, December 5th.

Can-Fite BioPharma Price Performance

CANF stock opened at $1.58 on Friday. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69. The firm’s 50-day moving average is $2.15 and its 200 day moving average is $2.47. The company has a market capitalization of $5.59 million, a PE ratio of -0.88 and a beta of 1.32.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. 21.00% of the stock is owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.